03.15.2019 | Frozen bags of shrimp in Canadian supermarkets could be carrying drug-resistant bacteria
Canadian Broadcasting Corporation (CBC) | Does your local supermarket sell products carrying drug-resistant bacteria? A Canadian research team set out to discover whether frozen shrimp sold in supermarkets were tainted with superbugs. Researchers found that of the 51 bags of frozen shrimp they tested, 17% contained bacteria such as E. coli and staph aureus, that showed resistance to at least one antibiotic. Although the Canadian Food Inspection Agency (CFIA) does not allow for the use of any antibiotics in domestic shrimp farming, the overuse of antibiotics in Asian shrimp aquaculture has some researchers and food inspectors concerned about the potential for antibiotic-resistant bacteria landing in Canada through imported seafood. Global demand for shrimp has exploded in recent decades, worth an estimated $39 billion US and growing. Canada alone imports about $700 million in shrimp each year, with the majority of it coming from countries like India, Vietnam, China and Thailand.
02.22.2019 | NIAID is calling for applications for funding for the development of antibiotics, vaccines and products products to address drug resistance
NIAID | The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting proposals for NIAID product development contracts focused on supporting efforts to develop new vaccines or therapeutic candidates targeting antibiotic-resistant bacterial infections. NIAID is also soliciting proposals for product development contracts to mitigate or treat injuries or exposure to ionizing radiation from a radiological or nuclear incident. The deadline for submitting proposals is May 20, 2019.
02.18.2019 | JPIAMR reports on 2017 investment in R&D
JPIAMR | The Joint Programming Initiative on Antimicrobial Research (JPIAMR) has created a dashboard that provides on-line access to information about public investment in AMR research by 22 JPIAMR member countries, the European Commission and Wellcome Trust for the year 2017. A total investment of 1,794 M€ in research was recorded in 1,939 projects. Of these, 76.2% of the total investment was for research projects in antibiotic resistance followed by 20.6% in anti-parasitic and 3.2% in anti-fungal resistance research. A majority of the grants (57.6%) targeted priority area therapeutics, followed by diagnostics (13.1%), interventions (11.3%), transmission (7.5%), surveillance (6.7%) and environment (3.8%).
02.05.2019 | WHO calls for help to establish an overview of the world’s pre-clinical pipeline to combat AMR, invites product developers to submit information
WHO | WHO has launched its first data call to establish a global overview of the pre-clinical pipeline of products that target the WHP Priority Pathogens, TB and/or Clostridium difficile. WHO is inviting companies, institutions and others to submit data on their pre-clinical projects by March 18, 2019. This initiative builds on WHO’s existing global analysis of therapeutics currently in clinical development.
02.05.2019 | US should act now to introduce package of pull incentives to reward the successful development of novel antibiotics
COALITION | A group of AMR industry and non-profit organizations have joined forces to urge the 116th US congress to introduce a package of financial incentives to reward the successful delivery of new antibiotics to the market. The pull incentives should aim to stabilize today’s market and ensure the viability of future development of novel antibiotics. The group includes the Infectious Diseases Society of America, the Pew Charitable Trusts, Trust for America’s Health, Antimicrobial Innovation Alliance, Antimicrobials Working Group and a number of companies conducting AMR research.
01.29.2019 | UK shows leadership on anti-microbial resistance: The FT View
FINANCIAL TIMES | The Financial Times Editorial Board has lauded the UK government's 5-year AMR strategy and 20-year vision as vital steps in the right direction, and has praised the UK’s leadership in establishing a new pricing model pilot to reward companies for antibacterial products approved for use. The reward would be based on value to the health system and patients, rather than commercial volume or value. The UK represents only 3 per cent of the world’s drugs market, so the pilot will not have much of an impact on its own. But as an inspiration to other countries and world leaders, if implemented effectively and funded adequately, it could be a game changer in the fight against drug resistant bacteria. Global public health depends on a coordinated response.
01.25.2019 | UK launches new payment model for antimicrobials and aims to cut the use of antibiotics as part of an ambitious 5-year plan
EUROPEAN BIOTECHNOLOGY | The UK government’s 5-year plan to tackle antimicrobial resistance has ambitious goals and is a positive first step forward in establishing a multinational effort to change the way antibiotic research is rewards and antibiotics are paid for. The plan announced a new model in which drug developers would be paid based on how valuable the medicines are to the patients and the health system, rather than on volume sold. The new model follows calls by DRIVE-AB and others for changes in the way antibiotic research is funded and the way antibiotics are paid for.
01.14.2019 | EMA Guideline on Evaluation of Medicinal Products for the Treatment of Bacterial Infections – Public Consultation Document
EUROPEAN MEDICINES AGENCY | The EMA published an updated version of proposed guidelines intended for public consultation. The proposed guidelines reflect efforts to harmonize with other regulatory agencies. The EMA is inviting feedback until the consultation period closes July 31, 2019.